Jove
Visualize
Contact Us

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevention of Fetal Alcohol Spectrum Disorders in Primary Care: Use of Office Champions Model to Address Alcohol Use.

Annals of family medicine·2026
Same author

Bell's Palsy.

Primary care·2025
Same author

Dapagliflozin (Farxiga) for Preventing Hospitalization for Heart Failure.

American family physician·2020
Same author

Benign Anorectal Conditions: Evaluation and Management.

American family physician·2020
Same author

Heart Failure with Preserved Ejection Fraction: Diagnosis and Management.

American family physician·2017
Same author

Ivermectin 1% Cream (Soolantra) for Inflammatory Lesions of Rosacea.

American family physician·2016
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 14, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Parkinson disease: an update.

John D Gazewood1, D Roxanne Richards, Karl Clebak

  • 1University of Virginia Health System, Charlottesville, VA, USA.

American Family Physician
|February 20, 2013
PubMed
Summary
This summary is machine-generated.

Parkinson disease (PD) affects 1% of Americans over 60. Early diagnosis and treatment, including carbidopa/levodopa, improve motor function and quality of life, though non-motor symptoms like fatigue and dementia are common.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: May 14, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

  • Neurology
  • Movement Disorders

Background:

  • Parkinson disease (PD) is a progressive neurodegenerative disorder affecting approximately 1% of Americans over 60.
  • Key symptoms include bradykinesia, rigidity, tremor, and postural instability, often mimicking other conditions, complicating early diagnosis.

Purpose of the Study:

  • To provide an overview of Parkinson disease diagnosis, treatment, and management of associated non-motor symptoms.
  • To emphasize the importance of accurate diagnosis and timely intervention.

Main Methods:

  • Review of current medical literature on Parkinson disease.
  • Discussion of diagnostic challenges and therapeutic strategies.

Main Results:

  • Carbidopa/levodopa is the most effective treatment for motor impairment.
  • Dopamine agonists and MAO-B inhibitors offer alternatives with fewer dyskinesias.
  • Deep brain stimulation is an option for refractory cases.
  • Therapies like occupational, physical, and speech therapy improve function.
  • Non-motor symptoms (fatigue, sleep issues, dementia, depression) are prevalent and impact quality of life.

Conclusions:

  • Early diagnosis and initiation of treatment are crucial for managing Parkinson disease motor symptoms and functional decline.
  • A multimodal approach, including medication and therapies, is essential for improving patient outcomes and quality of life.
  • Addressing non-motor symptoms is vital for comprehensive Parkinson disease care.